Major new phase in heart failure management
AHA 2015, Orlando, FL, USA
Video navigation menu
Clinical benefit of conventional inhibitors of the renin-angiotensin system (RAS). 0:01
The search for better ways to inhibit RAS. 0:32
Effects of simultaneous inhibition of RAS and neprilysin by sacubitril-valsartan (LCZ696). 1:18
Implications of the PARADIGM-HF trial for clinical practice. 2:25
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: